Kako citirati
Sažetak
Background: Procalcitonin (PCT), a biomarker closely associated with bacterial infections, has emerged as a valuable tool in guiding antibiotic therapy. In sepsis management, it may help optimize antibiotic use and improve clinical outcomes. This retrospective cohort study aimed to evaluate the effectiveness of PCT-guided antibiotic therapy in adult sepsis patients, with a particular focus on biochemical responses.
Methods: We retrospectively analyzed medical records of 110 adult sepsis patients admitted between January 2019 and December 2023. Patients were allocated to either a standard antibiotic group (n=53) or a PCT-guided antibiotic group (n=57). Key variables included demographic data, treatment duration, infection control metrics, and laboratory parameters such as white blood cell (WBC) count, C-reactive protein (CRP), and PCT levels before and after therapy.
Results: Compared to the standard group, the PCT-guided group exhibited significantly greater reductions in WBC, CRP, and PCT levels (P < 0.05), shorter antibiotic duration, fewer secondary infections, and improved antibiotic de-escalation rates. A higher complete response rate (17.54% vs. 3.77%) was also observed in the PCT-guided group. No significant difference was found in 28-day mortality.
Conclusions: PCT-guided antibiotic therapy led to more favorable changes in key biochemical markers and clinical outcomes, supporting its role as a biomarker-driven approach to antibiotic optimization in sepsis management.
Ključne reči
Sepsis
Biomarkers
Antibiotic therapy
C-reactive protein
White blood cells
Retrospective study
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.